Virtual Clinical Trials Market Research Report 2021: Extended Access Trials, Intervention Trials and Observational Trials – Global Forecast to 2025 – ResearchAndMarkets.com

DUBLIN – (BUSINESS WIRE) – “Virtual Clinical Trials Market Research Report according to study design (extended access trials, intervention trials and observational trials), implication (cardiovascular disease and oncology) – Global outlook to 2025 – cumulative effect of COVID-19 added in ResearchAndMarkets.com’s offer.

The global market for virtual clinical trials is expected to grow from $ 2,092.67 million in 2020 to $ 5,521.67 million by the end of 2025.

Cumulative impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so the long-term and projected effects will affect the growth of the industry over the projected period. Our ongoing research strengthens our research framework to ensure the inclusion of fundamental COVID-19 issues and potential pathways forward.

The report provides insight into COVID-19 in light of changes in consumer behavior and demand, purchasing patterns, supply chain reorientation, the dynamics of current market forces, and significant government intervention. The updated study provides insight, analysis, estimates and forecasts, taking into account the impact of COVID-19 on the market.

FPNV positioning matrix:

The FPNV positioning matrix assesses and categorizes suppliers in the virtual clinical trial market based on business strategy (business growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features, and customer support) that helps businesses in better decision making and understanding of the competitive environment.

Strategic competition window:

The Strategic Competition Window analyzes the competitive landscape in terms of markets, applications, and geographic areas. The strategic competition window helps the supplier to define the alignment or fit between its capabilities and the prospects for future growth prospects.

During the envisaged period, it defines the optimal or favorable suitability of suppliers to adopt successive merger and acquisition strategies, geographical expansion, research and development and new product introduction strategies for further expansion and growth of the business.

Key topics:

1. Preface

1.1. Objectives of the study

1.2. Market segmentation and coverage

1.3. Years considered for study

1.4. Currency and prices

1.5. Language

1.6. Restrictions

1.7. Stakeholders

2. Research methodology

2.1. Research process

2.2. Execution of research

2.3. Research outcome

3. Summary

3.1. Introduction

3.2. Market Outlook

3.3. Outlook Design Outlook

3.4. Implication Outlook

3.5. Geography Outlook

3.6. Competitor Outlook

4. Market overview

4.1. Introduction

4.2. Cumulative impact of COVID-19

5. Market insight

5.1. Market dynamics

5.1.1. Drivers

5.1.1.1. Increasing adoption of telehealth

5.1.1.2. The growing adoption of digitalization in healthcare globally

5.1.1.3. Proliferation of research and development activities, together with favorable government support

5.1.2. Restrictions

5.1.2.1. Concerns about high data collection, accuracy and reliability of data, and technological failure

5.1.3. Opportunities

5.1.3.1. Current technological advances in healthcare

5.1.3.2. New collaboration between biotechnology companies and clinical research companies

5.1.4. Challenges

5.1.4.1. A cumbersome and difficult process with enrollment and engagement

5.2. Five-force carrier analysis

5.2.1. Threat to new participants

5.2.2. Threat of replacements

5.2.3. Negotiating power of customers

5.2.4. Vendor bargaining power

5.2.5. Industrial rivalry

6. Global market of virtual clinical trials, according to the study design

6.1. Introduction

6.2. Extended access experiments

6.3. Interventional trials

6.4. Observational examinations

7. Global market for virtual clinical trials, implied

7.1. Introduction

7.2. Cardiovascular diseases

7.3. Oncology

8. U.S. Virtual Clinical Trials Market

8.1. Introduction

8.2. Argentina

8.3. Brazil

8.4. Canada

8.5. Mexico

8.6. United States

9. Asia-Pacific Virtual Clinical Trials Market

9.1. Introduction

9.2. Australia

9.3. china

9.4. India

9.5. Indonesia

9.6. Japan

9.7. Malaysia

9.8. Philippines

9.9. north korea

9.10. Thailand

10. Virtual Clinical Trials Market for Europe, the Middle East and Africa

10.1. Introduction

10.2. France

10.3. Germany

10.4. Italy

10.5. The Netherlands

10.6. Qatar

10.7. Russia

10.8. Saudi Arabia

10.9. South Africa

10.10. Spain

10.11. United Arab Emirates

10.12. UK

11. Competitive landscape

11.1. FPNV positioning matrix

11.1.1. Quadrants

11.1.2. Business strategy

11.1.3. Product satisfaction

11.2. Market ranking analysis

11.3. Market share analysis

11.4. SWOT analysis of the competitor

11.5. Competitive scenario

11.5.1. Merger and acquisition

11.5.2. Agreement, cooperation and partnership

11.5.3. Launch and improvement of a new product

11.5.4. Investments and financing

11.5.5. Award, recognition and expansion

12. Useful company profiles

12.1. AiCure LLC

12.2. Clinical ink by a GI partner

12.3. CliniOps, Inc.

12.4. Covance Inc.

12.5. CRF Health By Genstar Capital

12.6. ERT

12.7. Everest Global, Inc.

12.8. ICON PLC

12.9. IQVIA

12.10. LEO Innovation Lab

12.11. Medable, Inc.

12.12. Medidata Solutions

12.13. Medpace

12.14. Navitas Life Sciences, Inc.

12.15. Neoteryx, LLC

12.16. Oracle Corporation

12.17. Parexel International

12.18. Pfizer Inc.

12.19. Science 37

12.20. Tenthpin Management Consultants AG

12.21. VirTrial, LLC

For more information on this report, visit https://www.researchandmarkets.com/r/eibu93

Source